Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States

被引：26

作者：

Grant, Linda Ahdieh ^{[1
]}

Dunne, Eileen F. ^{[1
]}

Chesson, Harrell ^{[1
]}

Markowitz, Lauri E. ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA

来源：

VACCINE | 2011年 / 29卷 / 13期

关键词：

HPV vaccine; Mid adult women; Older women; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-EFFECTIVENESS; NATURAL-HISTORY; RISK-FACTORS; INFECTION; HEALTH; PERSISTENCE; DURATION; GUANACASTE; COHORT;

D O I：

10.1016/j.vaccine.2011.01.032

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In the United States, human papillomavirus (HPV) vaccination is recommended for 11 or 12 year old girls, with catch-up vaccination through age 26 years. Data are available for women over the age of 26 years on immunogenicity for both quadrivalent and bivalent HPV vaccines and on efficacy for the quadrivalent HPV vaccine. If HPV vaccines are licensed for use in women over 26 years of age (mid-adult women), recommendations for this age group will need to be considered. This review summarizes vaccine efficacy and immunogenicity data in mid-adult women, and addresses epidemiologic data related to key questions for consideration of vaccine recommendations for women over age 26 years. Published by Elsevier Ltd.

引用

页码：2365 / 2370

页数：6

共 48 条

[11] Model for assessing human papillomavirus vaccination strategies [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. ;

Insinga, Ralph P. .

EMERGING INFECTIOUS DISEASES, 2007, 13 (01) :28-41

[12] Age-Based Programs for Vaccination against HPV [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. ;

Insinga, Ralph P. ;

Haupt, Richard M. ;

Barr, Eliav .

VALUE IN HEALTH, 2009, 12 (05) :697-707

[13]

FERRIS D, 2010, 26 INT PAP C MONTR

[14]

Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1

[15] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases [J].

Garland, Suzanne M. ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Harper, Diane M. ;

Leodolter, Sepp ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Steben, Marc ;

Bryan, Janine ;

Taddeo, Frank J. ;

Railkar, Radha ;

Esser, Mark T. ;

Sings, Heather L. ;

Nelson, Micki ;

Boslego, John ;

Sattler, Carlos ;

Barr, Eliav ;

Koutsky, Laura A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) :1928-1943

[16] Modelling the impact of HPV vaccines on cervical cancer and screening programmes [J].

Garnett, Geoffrey P. ;

Kim, Jane J. ;

French, Katherine ;

Goldie, Sue J. .

VACCINE, 2006, 24 :178-186

[17] Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine [J].

Goldie, SJ ;

Kohli, M ;

Grima, D ;

Weinstein, MC ;

Wright, TC ;

Bosch, FX ;

Franco, E .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (08) :604-615

[18]

HAUPT R, 2008, M ADV COMM IMM PRACT

[19] Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica [J].

Herrero, R ;

Castle, PE ;

Schiffman, M ;

Bratti, MC ;

Hildesheim, A ;

Morales, J ;

Alfaro, M ;

Sherman, ME ;

Wacholder, S ;

Chen, S ;

Rodriguez, AC ;

Burk, RD .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) :1796-1807

[20] Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles [J].

Ho, GYF ;

Studentsov, Y ;

Hall, CB ;

Bierman, R ;

Beardsley, L ;

Lempa, M ;

Burk, RD .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (06) :737-742

← 1 2 3 4 5 →